Supplementary Figures S1-S7 from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

Supplementary Figures S1-S7. WT52 inhibits both HGF-dependent and -independent MET autophosphorylation (S1); MET-targeted ADCC prevents tumor recurrence and suppresses metastatic dissemination in an adjuvant orthotopic model of mammary carcinoma (S2); Circulating tumor cell number shows direct correlation with the extent of metastatic dissemination (S3); Germlining of the WT52 antibody (S4); ARGX-111, an antagonistic anti-MET antibody endowed with enhanced ADCC activity (S5); ARGX-111 reduces total MET protein levels without promoting receptor shedding (S6); ARGX-111 displays enhanced ADCC compared to fucosylated G52 (S7).